Boehringer Ingelheim has lined up an option on the schizophrenia drugs under development at GSK spinout Autifony, including the lead therapy AUT00206.

Boehringer agreed to pay up to €627.5 million for global rights to its Kv3 modulators. And after advancing the work on schizophrenia, the partners want to branch out into Fragile X and other CNS ailments.